Anemia biotech Akebia Therapeutics sets terms for $76 million IPO
Anemia biotech Akebia Therapeutics sets terms for million IPO Akebia Therapeutics, a biotech developing an anemia treatment with a once-daily oral dose, announced terms for its IPO on Friday. The...
View ArticleHalozyme Therapeutics Could Bring New Hope for Diabetes Patients
Halozyme Therapeutics Could Bring New Hope for Diabetes Patients The health of the U.S. population has been on a steady decline for the past several decades. Many researches have already cautioned...
View ArticleINSYS Therapeutics Inc.: Insys Therapeutics Reports Second Quarter 2014 …
INSYS Therapeutics Inc.: Insys Therapeutics Reports Second Quarter 2014 … … for pain, with an End-of-Phase II Meeting scheduled in the fourth quarter of this year. We also plan to file INDs for...
View Article
More Pages to Explore .....
